Latest news with #Genflow
Associated Press
17-07-2025
- Business
- Associated Press
Genflow Confirms Progression of Grant
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Genflow Confirms Approximately €4M Grant Support from Wallonia Region; GF-1002 Program Progressing without Interruption LONDON, UK / ACCESS Newswire / July 17, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ('Genflow' or 'the Company'), the only publicly listed longevity company in Europe, is pleased to reaffirm the previously announced award of approximately €4 million in non-dilutive financial support from the Wallonia Region of Belgium, supporting the development of its lead gene therapy candidate, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH). Read the RNS announcing this grant here. The support package spans a three-year development program, aligned with Genflow's existing clinical roadmap. All project-related expenses incurred in 2025 will be considered eligible. While initial disbursement is pending the completion of standard administrative procedures on the government's side, Genflow has taken proactive steps to ensure the continuity of its GF-1002 program and confirms that progress remains on track with no delays to planned research or development activities. Dr. Eric Leire, CEO of Genflow, commented: 'We greatly appreciate the continued support from the Wallonia Region. The €4 million in non-dilutive funding represents a significant endorsement of our science and our strategy. We remain fully focused on advancing GF-1002 through the next stage of development and have ensured that operations proceed uninterrupted as the program moves forward.' Contacts About Genflow Biosciences Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and X. DISCLAIMER The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words 'anticipate', 'believe', 'continue', 'could', 'estimate', 'expect', 'intend', 'may', 'might', 'plan', 'possible', 'potential', 'predict', 'project', 'seek', 'should', 'would' and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions. Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: Genflow Biosciences PLC press release
Globe and Mail
28-05-2025
- Business
- Globe and Mail
Genflow Biosciences and CER Sign Master Service Agreement to Strengthen Long-Term R&D Collaboration
LONDON, UK / ACCESS Newswire / May 28, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to announce the signing of a Master Service Agreement (MSA) with CER Groupe (CER), a long-standing partner of the Company. CER is a private Belgian research center offering integrated bioproduction and pre-clinical services within a regulated ISO and GxP-compliant environment. The MSA formalizes the working relationship between Genflow and CER, providing a robust R&D framework to accelerate Genflow's pre-IND gene therapy programs. Under the terms of the MSA, Genflow and CER will: Develop, produce and characterize Genflow's gene therapy candidates; Implement a collaborative project management system to drive efficient execution and timely deliverables supporting Genflow's goals with standardized templates for Task Orders and technical services; and Combine scientific expertise derisks, innovate and ensure relevant scientific outcomes. Said Dr. Eric Leire, CEO of Genflow: " Our partnership with CER has been instrumental in supporting our R&D efforts to date. Formalizing this collaboration through the MSA will enable greater operational alignment and strategic agility as we continue to accelerate our pipeline." Contacts Corporate Brokers Capital Plus Partners Ltd Jon Critchley, +44 0203 821 6168 About Genflow Biosciences Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and X. About CER Groupe CER Groupe is a GLP-certified private Belgian research center supporting European life sciences innovation for more than 45years. CER's 200 colleagues gather cutting-edge expertise ensuring high quality integrated bioproduction and non-clinical services. CER supports companies in progressing their development from idea generation up to IND-enabling studies. CER Groupe favors collaborative and agile approaches accelerating companies' access to clinical stage development. Visit to learn what CER's partners say and follow CER Groupe on LinkedIn to stay up-to-date on CER's latest developments. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit View the original press release on ACCESS Newswire
Yahoo
22-05-2025
- Business
- Yahoo
Genflow Biosciences PLC Announces AGM Notice
LONDON, UNITED KINGDOM / / May 22, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting ("AGM") at 9am on Thursday 12 June 2025 at One Heddon Street, London, W1B 4BD. The Notice of the AGM ("Notice") and 2025 Form of Proxy will shortly be available on the Company's website, and was, where applicable, posted to shareholders on 19 May 2025. Further details of the arrangements for this year's AGM are set out in the Notice. As announced on 30 April 2025, the Company's Annual Report and Accounts for the year ended 31 December 2024 are also available on the website and has, where applicable, also been posted to registered shareholders. Contacts Genflow Biosciences Harbor Access Dr Eric Leire, CEO Jonathan Paterson, Investor Relations +32-477-495-881 +1 475 477 9401 Brokers Capital Plus Partners Ltd Dominic Berger, +44 203 821 6167 Jon Critchley, +44 0203 821 6168 About Genflow Biosciences Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and Twitter/X. -Ends- This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
Genflow Biosciences PLC Announces Key SIRT6 Patent Application
LONDON, UNITED KINGDOM / / May 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, announces that the Japanese Patent Office has advanced its SIRT6-related patent application (Application No. JP 2024515284) to the national examination phase. The application, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was originally filed on 13 May 2022 and is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusive license to this intellectual property. The invention covers novel SIRT6 gene variants that play a central role in genomic stability, metabolic regulation, and healthy aging. These variants underpin Genflow's core therapeutic platform and represent a key part of its pipeline targeting age-related diseases. The progression to national examination in Japan marks an important step in Genflow's strategy to establish broad international patent protection. Japan, with one of the world's most rapidly aging populations, is a priority market for longevity-related innovation. Dr. Eric Leire, CEO of Genflow Biosciences, commented: "We are pleased to see continued momentum in the protection of our SIRT6 intellectual property. Japan represents a strategically important jurisdiction for Genflow, and advancing this patent application strengthens our global positioning as a leader in longevity gene therapy." Genflow continues to progress its preclinical and clinical programs targeting age-related pathologies using the SIRT6 gene variants. Contacts Genflow Biosciences Harbor Access Dr Eric Leire, CEO Jonathan Paterson, Investor Relations +32-477-495-881 +1 475 477 9401 Corporate Brokers Capital Plus Partners Ltd Jon Critchley, +44 0203 821 6168 About Genflow Biosciences Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and Twitter/X. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
14-04-2025
- Business
- Associated Press
Genflow Biosciences PLC Announces Launch of AI-Powered Partnership
Genflow Biosciences Signs MSA with Heureka Labs, Launching AI-Powered Partnership in Gene Therapy Research LONDON, UNITED KINGDOM / ACCESS Newswire / April 14, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ('Genflow' or 'the Company'), the only publicly listed longevity company in Europe, is pleased to announce that, in addition to the recently announced launch of a new development program in ophthalmology, it has entered into a strategic partnership with Heureka Labs, Inc., a U.S.-based AI-driven discovery and analytics platform. A Master Services Agreement ('MSA') was signed by both parties on 11 April 2025, establishing a framework for long-term collaboration. Under the terms of the MSA, Heureka Labs, a technology spin-off from Duke University, will provide Genflow with access to its proprietary artificial intelligence ('AI') platform, which specializes in the analysis of high-dimensional genomic data including RNA sequencing and gene expression profiles. The application of Heureka's AI technology is expected to enhance Genflow's ability to interpret complex biological datasets, enabling deeper insights into gene regulatory networks and systemic biological responses. These insights will be key to optimising therapeutic design and anticipating patient-specific outcomes. Genflow will retain all IP rights under the MSA. Initial efforts will support the Company's lead candidate, GF-1002, a centenarian SIRT6-based gene therapy currently in preclinical evaluation and may extend to future pipeline gene therapy programs, including those targeting Metabolic Dysfunction-Associated Steatohepatitis ('MASH'). Heureka's AI platform is designed to accelerate drug discovery processes by generating testable hypotheses, uncovering unexpected biological patterns, and improving the efficiency of research and development workflows. The platform is currently in use by leading pharmaceutical and biotechnology companies. 'Incorporating AI is no longer optional in bioinformatics research-it's essential for precision, speed, and scale,' said Dr. Eric Leire, CEO of Genflow. 'Heureka's AI platform gives us the tools to navigate complex biological data and refine our gene therapy approach across a number of programs we are working on, accelerating the delivery of safe and effective therapies that promote a healthier lifespan, while helping to ease the growing operational and economic burden of an aging population.' Contacts About Genflow Biosciences Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and X. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: Genflow Biosciences PLC press release
